Evidence map›Paper›PMID 29695631›Full record

ArticleMolecular cancer therapeutics2018

Improving the

Gilad Kaplan, Ronit Mazor, Fred Lee, Youjin Jang, Yasmin Leshem, Ira Pastan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Antibody-drug conjugates: Recent advances in payloads.Acta pharmaceutica Sinica. B · 2023
    Review
  2. Review
  3. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.International journal of molecular sciences · 2020
    Review
  4. Immunogenicity of Immunotoxins ContainingFrontiers in immunology · 2020
    Review
  5. Article
  6. Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gilad Kaplan *Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Ronit Mazor *Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Fred LeeLaboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Youjin JangLaboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Yasmin LeshemLaboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Ira PastanLaboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland. pastani@mail.nih.gov.

Funding

Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical StudiesZIABC008753 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PASTAN, IRA · 2009 to 2024
$33.1M
IMMUNOTOXIN THERAPY OF SOLID AND HEMATOPOIETIC TUMORS: PRECLINICAL STUDIESZ01BC008753 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PASTAN, IRA · 1996 to 2008
$3.2M
Intramural NIH HHS Z01 BC008753
6 · The paper itself

Abstract

Tac (CD25) is expressed on multiple hematologic malignancies and is a target for cancer therapies. LMB-2 is an extremely active anti-Tac recombinant immunotoxin composed of an Fv that binds to Tac and a 38-kDa fragment of

Indexed as

Protein EngineeringADP Ribose TransferasesAnimalsAntibodies, MonoclonalBacterial ToxinsCell Line, TumorCell ProliferationCytotoxicity, ImmunologicExotoxinsHematologic NeoplasmsHumansInterleukin-2 Receptor alpha SubunitMesothelinMicePoint MutationProtein DomainsADP Ribose TransferasesAntibodies, MonoclonalB3(Fv)-PE38KDEL recombinant immunotoxinBacterial ToxinsExotoxinsInterleukin-2 Receptor alpha SubunitMesothelinMsln protein, mousePseudomonas aeruginosa Exotoxin ASialic Acid Binding Ig-like Lectin 2Virulence Factors

Identifiers

PMID29695631
PMCPMC6030476

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.